Internal Medicine, Nephrology · Lima, OH
NPI
1982918199
Since 2010
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
750 W High St, Suite 150
Lima, OH, 45801
Phone (419) 227-1359
Groups this clinician bills Medicare through
Medicare paid, 2024
$253K
3,204 services
Medicare patients, 2024
829
Average age 76
Drug cost, 2024
$327K
3,205 prescriptions
Company payments, 2025
$676
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Vivek Agarwal was code 99232 (hospital e&m - subsequent), 1,269 times for 272 patients. In total Vivek Agarwal billed 3,204 services in 18 codes, and Medicare paid $253K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-03-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 1,269 | 272 | $59.16 | $75K |
| 99213 Office E&M - Established | Office | 622 | 448 | $45.95 | $29K |
| 99222 Hospital E&M - Initial | Facility | 225 | 167 | $96.54 | $22K |
| 99214 Office E&M - Established | Office | 154 | 127 | $66.02 | $10K |
| 90960 ESRD Related Services (not dialysis) | Office | 150 | 23 | $264.77 | $40K |
| 99233 Hospital E&M - Subsequent | Facility | 137 | 75 | $88.03 | $12K |
| 90935 Hemodialysis | Facility | 96 | 41 | $53.45 | $5,131 |
| 90961 ESRD Related Services (not dialysis) | Office | 87 | 26 | $217.01 | $19K |
| 99204 Office E&M - New | Office | 83 | 83 | $108.18 | $8,979 |
| 99213 Office E&M - Established | Facility | 43 | 38 | $43.76 | $1,882 |
| 99223 Hospital E&M - Initial | Facility | 37 | 37 | $128.03 | $4,737 |
| 90945 Peritoneal Dialysis | Facility | 35 | 11 | $64.00 | $2,240 |
| 99204 Office E&M - New | Facility | 20 | 20 | $85.76 | $1,715 |
By year: 2022 $257K for 3,109 services; 2023 $260K for 3,085 services; 2024 $253K for 3,204 services.
Medicare prescription drug claims, 2024
In 2024, the drug Vivek Agarwal prescribed most often to Medicare patients was Losartan Potassium, with 265 prescriptions and refills. In total Vivek Agarwal wrote 3,205 Medicare prescriptions that cost $327K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Losartan Potassium Generic | 265 | 703 | 96 | $2,376 |
| Furosemide Generic | 263 | 605 | 83 | $1,015 |
| Bumetanide Generic | 223 | 420 | 72 | $6,701 |
| Hydralazine Hcl Generic | 218 | 434 | 67 | $2,253 |
| Amlodipine Besylate Generic | 214 | 488 | 73 | $992 |
| Potassium Chloride Generic | 213 | 423 | 69 | $4,117 |
| Lisinopril Generic | 188 | 474 | 60 | $835 |
| Carvedilol Generic | 179 | 405 | 61 | $1,120 |
| Doxazosin Mesylate Generic | 124 | 271 | 37 | $2,038 |
| Sevelamer Carbonate Generic | 110 | 152 | 27 | $11K |
| Clonidine Hcl Generic | 104 | 198 | 27 | $751 |
| Allopurinol Generic | 75 | 186 | 21 | $441 |
| Klor-Con M20 Potassium Chloride | 68 | 174 | 25 | $1,492 |
| Tamsulosin Hcl Generic | 60 | 144 | 16 | $638 |
| Midodrine Hcl Generic | 59 | 98 | 16 | $5,405 |
Brand drugs: - claims; generic drugs: 2,926 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vivek Agarwal $676 ($676 in general payments such as food, travel and fees) from 8 companies. The largest payer was Novartis Pharmaceuticals Corporation with $248.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 11 | $248 |
| Amgen Inc. AMGN | 12 | $215 |
| Fresenius USA Marketing, Inc. | 4 | $74.35 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 2 | $50.78 |
| Novo Nordisk Inc NVO | 2 | $46.08 |
| OPKO Pharmaceuticals, LLC | 1 | $19.56 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $14.77 |
| Travere Therapeutics, Inc. TVTX | 5 | $7.01 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.